Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Average Recommendation of "Strong Buy" from Brokerages

Key Points

• Zealand Pharma A/S has received an average consensus recommendation of "Buy" from seven brokerages, with five analysts labeling it as a "strong buy."
• The company's latest earnings report indicated earnings per share of $16.06, which fell short of analyst expectations of $16.72.
• As of the latest updates, Zealand Pharma A/S shares opened at $69.02 and have a market capitalization of $4.90 billion with a twelve-month price range between $49.98 and $136.76.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) has received an average recommendation of "Strong Buy" from the seven brokerages that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, one has assigned a buy recommendation and five have assigned a strong buy recommendation to the company.

ZLDPF has been the topic of a number of recent research reports. BNP Paribas raised Zealand Pharma A/S to a "strong-buy" rating in a report on Tuesday, July 1st. Barclays upgraded shares of Zealand Pharma A/S to a "strong-buy" rating in a research note on Monday, July 7th. Zacks Research raised shares of Zealand Pharma A/S from a "strong sell" rating to a "hold" rating in a report on Monday. Finally, Wells Fargo & Company raised shares of Zealand Pharma A/S to a "strong-buy" rating in a research report on Thursday, July 24th.

Zealand Pharma A/S Stock Performance

Shares of OTCMKTS:ZLDPF traded down $1.24 on Friday, reaching $72.07. 111 shares of the company's stock were exchanged, compared to its average volume of 860. The company has a market capitalization of $5.12 billion, a price-to-earnings ratio of 5.06 and a beta of 0.73. The company has a fifty day moving average of $60.98 and a 200-day moving average of $65.55. Zealand Pharma A/S has a twelve month low of $49.98 and a twelve month high of $135.65. The company has a current ratio of 15.09, a quick ratio of 15.08 and a debt-to-equity ratio of 0.02.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported $16.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $16.72 by ($0.66). The business had revenue of $1.43 billion during the quarter, compared to the consensus estimate of $9.18 billion. Zealand Pharma A/S had a net margin of 73.90% and a return on equity of 67.06%. On average, research analysts predict that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.